Spotlight On... AstraZeneca moves quickly to shed another noncore drug in ProStrakan deal; India's Odisha state eyes drug manufacture parks; Chuikyo fee revisions in focus; and more...

U.K. multinational AstraZeneca ($AZN) announced a second deal in Asia in as many days to sell a noncore drug, fetching $70 million from a unit of Tokyo-based Kyowa Hakko Kirin. The latest deal sees ProStrakan, based in Galashiels, Scotland, buy European rights to Moventig, a drug that treats opioid-induced constipation, AstraZeneca said in a press release. ProStrakan will also pay AstraZeneca unspecified tiered double-digit royalties and potential milestones. On Monday, the company announced a deal with third-party distributor China Medical Systems Holding for rights to two cardio drugs that garnered $500 million. The effort by AstraZeneca to shed noncore drugs is aimed at building cash pile for pipeline products that hold blockbuster promise. Release

> India's Odisha state plans to build industrial parks for API manufacture. Report

> The process of setting fees charged by Japan's hospitals, pharmacies and medical personnel under the Central Social Insurance Medical Council, or Chuikyo, has come into the spotlight ahead of fee revisions slated to come into notice on April 1. Report

> U.S.-based Medidata announced that Beijing-based R&G Pharma Studies became the first Chinese customer to use Medidata's clinical trial management technology Medidata CTMS. Release

Suggested Articles

The FDA is bracing for drug and medical supply shortages in the U.S. as the COVID-19 outbreak from China continues to spread globally.

While no shortages of drug supplies have been reported, governments are trying to get a handle on what they can do if they materialize.

A Chinese company's producing a remdesivir generic. Daiichi expects $18 million in Enhertu Q1 sales. Tecentriq becomes seventh PD-1/L1 to enter China.